{"id":"s-1-cisplatin-arm-a","safety":{"commonSideEffects":[{"rate":"40-60","effect":"Neutropenia"},{"rate":"30-50","effect":"Anemia"},{"rate":"20-40","effect":"Thrombocytopenia"},{"rate":"50-70","effect":"Nausea/vomiting"},{"rate":"20-40","effect":"Diarrhea"},{"rate":"10-30","effect":"Stomatitis"},{"rate":"10-20","effect":"Nephrotoxicity"},{"rate":"5-15","effect":"Ototoxicity"},{"rate":"10-25","effect":"Peripheral neuropathy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"S-1 (tegafur/gimeracil/oteracil potassium) is converted to fluorouracil in tumor tissue and inhibits thymidylate synthase, disrupting DNA synthesis. Cisplatin forms DNA adducts and cross-links, preventing DNA replication and transcription. The combination exploits complementary mechanisms of action to enhance cell death in rapidly dividing cancer cells.","oneSentence":"S-1 is an oral fluoropyrimidine prodrug that inhibits thymidylate synthase and other enzymes in nucleotide synthesis, while cisplatin is a platinum-based alkylating agent that cross-links DNA, together producing synergistic cytotoxic effects against cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:33:07.202Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Gastric cancer"},{"name":"Gastroesophageal junction cancer"},{"name":"Esophageal cancer"}]},"trialDetails":[{"nctId":"NCT05771480","phase":"PHASE3","title":"Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-08-16","conditions":"Biliary Tract Cancer","enrollment":142},{"nctId":"NCT06109779","phase":"PHASE3","title":"Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-12-04","conditions":"Biliary Tract Cancer","enrollment":757},{"nctId":"NCT05535166","phase":"PHASE2","title":"Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2022-12-20","conditions":"Medulloblastoma","enrollment":130},{"nctId":"NCT01878617","phase":"PHASE2","title":"A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2013-06-23","conditions":"Medulloblastoma","enrollment":660},{"nctId":"NCT06422858","phase":"PHASE2","title":"Sequential Tegafur-gimeracil-oteracil Potassium Capsule (s-1) and Serplulimab Following Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2024-05-20","conditions":"Locally Advanced Inoperable Esophageal Squamous Cell Carcinoma","enrollment":37},{"nctId":"NCT01285557","phase":"PHASE3","title":"Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial","status":"TERMINATED","sponsor":"Taiho Oncology, Inc.","startDate":"2011-04-14","conditions":"Metastatic Diffuse Gastric Cancer Including Carcinoma of the Gastro-esophageal Junction","enrollment":361},{"nctId":"NCT00400179","phase":"PHASE3","title":"A Safety and Efficacy Study in Patients With Gastric Cancer","status":"COMPLETED","sponsor":"Taiho Oncology, Inc.","startDate":"2005-05","conditions":"Gastric Cancer","enrollment":1053},{"nctId":"NCT03617133","phase":"PHASE2","title":"Image Guided IMRT, Radiochemotherapy and MRI-based IGABT in Locally Advanced Cervical Cancer","status":"RECRUITING","sponsor":"Medical University of Vienna","startDate":"2016-04","conditions":"Uterine Cervical Neoplasms","enrollment":1000},{"nctId":"NCT02128243","phase":"PHASE2","title":"Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer","status":"COMPLETED","sponsor":"AIO-Studien-gGmbH","startDate":"2014-09","conditions":"Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction, Gastric Neoplasm, Gastroesophageal Junction Adenocarcinoma","enrollment":242},{"nctId":"NCT00770874","phase":"PHASE3","title":"Phase III Study of S-1 + Cisplatin vs Cisplatin in Cervical Cancer","status":"COMPLETED","sponsor":"Taiho Pharmaceutical Co., Ltd.","startDate":"2008-09","conditions":"Cervical Cancer","enrollment":375},{"nctId":"NCT02878889","phase":"PHASE2","title":"A Phase II Trial of S-1 as Maintenance Treatment After Gemcitabine Plus Cisplatin Regimen Chemotherapy in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma.","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2016-08","conditions":"Nasopharyngeal Carcinoma","enrollment":53},{"nctId":"NCT01388790","phase":"PHASE2","title":"Cetuximab in Combination With S-1 and Cisplatin in Gastric Cancer","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2011-06","conditions":"Gastric Cancer","enrollment":40},{"nctId":"NCT00874328","phase":"PHASE1, PHASE2","title":"A Study of TS-1 Plus Irinotecan and Cisplatin (IP) for Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)","status":"UNKNOWN","sponsor":"National Cancer Center, Korea","startDate":"2008-10","conditions":"Advanced Non-Small Cell Lung Cancer","enrollment":74}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"S-1 + Cisplatin (arm A)","genericName":"S-1 + Cisplatin (arm A)","companyName":"Taiho Pharmaceutical Co., Ltd.","companyId":"taiho-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"S-1 is an oral fluoropyrimidine prodrug that inhibits thymidylate synthase and other enzymes in nucleotide synthesis, while cisplatin is a platinum-based alkylating agent that cross-links DNA, together producing synergistic cytotoxic effects against cancer cells. Used for Gastric cancer, Gastroesophageal junction cancer, Esophageal cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}